- Home
- IXHL vs BTAI Comparison
IXHL vs BTAI Comparison
Compare IXHL & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IXHL | BTAI |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.6M | 35.6M |
| IPO Year | 2024 | 2018 |
Fundamental Metrics
Financial Performance| Metric | IXHL | BTAI |
|---|---|---|
| Price | $5.95 | $1.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.33 |
| AVG Volume (30 Days) | ★ 4.1M | 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $261.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $1.17 |
| 52 Week High | $5.45 | $8.08 |
Technical Indicators
Market Signals| Indicator | IXHL | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 90.18 | 46.64 |
| Support Level | $0.31 | $1.50 |
| Resistance Level | N/A | $2.18 |
| Average True Range (ATR) | 0.37 | 0.14 |
| MACD | 0.40 | 0.00 |
| Stochastic Oscillator | 91.05 | 31.58 |
Price Performance
Historical ComparisonAbout IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.